Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status: where the two records stand today

Wolverine legal status is a status story, and its newest entry is a meeting that has already taken place. The FDA Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026 with both components of BPC-157 TB-500 on its agenda as bulk drug substances being considered for inclusion on the 503A Bulks List ^[12]. As of September 2026, FDA has published no record of the committee's votes.

The present-tense fact underneath it is narrower. FDA placed both constituents of the Wolverine blend in 503A "Category 2" with its September 29, 2023 nominated-substances update, citing potentially significant safety risks ^[10][11]; on the agency's page dated April 22, 2026, their nominations are shown as withdrawn rather than remaining in Category 2. Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding ^[10], and FDA has not said whether a withdrawn nomination leaves a pharmacy in that same position. Neither peptide is an FDA-approved drug, and the blend has no approved therapeutic indication.

Both things are true at once: the 2023 classification is no longer what FDA's table shows, and the withdrawal that replaced it is not a clearance. Nothing here predicts the meeting's outcome. A PCAC discussion is advisory — a step in evaluation, not a final listing decision ^[12].

How FDA now lists BPC-157 and TB-500

Under the Federal Food, Drug, and Cosmetic Act, compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[10]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; otherwise it must be nominated and evaluated by FDA, with input from PCAC ^[10].

FDA's interim policy sorted nominated substances into categories. Category 1 substances "may be eligible" for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances were nominated with enough information to evaluate but were identified by FDA as raising significant safety risks — and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[10]. FDA's current table shows the nominations for BPC-157 and TB-500 were pulled, although FDA continues to publish concerns about immunogenicity for certain routes, peptide-related impurities, and active-ingredient characterization ^[11].

Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC. Being discussed by PCAC is a step in that evaluation — not a final listing decision, and not a change in current status ^[12].

Both components were on the July 23-24, 2026 PCAC agenda

There is no component carve-out in the Wolverine blend. Both records went to the same July review. FDA's public advisory-committee calendar lists the BPC-157 entries ("BPC-157 (free base)" / "BPC-157 acetate") and the TB-500 entries ("TB-500 (free base)" / "TB-500 acetate") among the bulk drug substances being considered for inclusion on the 503A Bulks List at the July 23-24, 2026 PCAC meeting ^[12].

FDA identifies the second withdrawn entry as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the same Ac-LKKTETQ heptapeptide that is one of the two peptides in this blend ^[11]. The BPC-157 and TB-500 nominations were both taken back; FDA staff later proposed against listing either one, and FDA had published no record of the committee's votes as of September 2026 ^[12].

What the agenda does not do is decide anything. No outcome from the July 2026 meeting is on FDA's public record; the calendar confirms only that these substances were set down for discussion as candidates ^[12]. No bulks-list decision has followed, none is dated, and none is certain.

How legally compounded peptide access works

Independent of any single substance's status, the lawful pathway for a compounded medication in the U.S. is well defined. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate ^[13]. Telehealth is one channel for that prescriber-evaluation step; it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances may be compounded ^[13].

If a compounded preparation is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, an FDA-registered 503B outsourcing facility ^[13].

The ingredient-eligibility caveat is the gate. FDA's withdrawn entries retain the agency's safety concerns, but the agency has not explained how a pharmacy should treat a withdrawn nomination under the 503A/503B bulk-substance rules ^[11][13]. That is the current position for both BPC-157 and TB-500. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.

WADA status of both constituents

Outside the compounding question, both constituents are prohibited in sport. The World Anti-Doping Agency lists BPC-157 under its S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 falls under prohibited peptide, growth-factor, and tissue-repair categories. For athletes subject to anti-doping rules, the blend is banned in and out of competition for the relevant classes. This is a status fact, not a recommendation; the page does not advise on use.

Is Wolverine (BPC-157 + TB-500) legal?

Neither component is an FDA-approved drug, and the blend has no approved therapeutic indication. FDA's April 22, 2026 page instead shows both nominations were withdrawn, keeps the agency's safety concerns beside them, and has not said whether that withdrawal changes a pharmacy's ability to compound either ingredient ^[10][11]. Both were on the July 23-24, 2026 PCAC agenda as bulks-list candidates, and no record of the committee's votes has been published ^[12].

Can you get BPC-157 from a compounding pharmacy?

The record gives no clear answer. FDA's current page shows BPC-157's nomination was withdrawn and retains the agency's published safety rationale; the agency has not stated what a 503A pharmacy may do with the ingredient after that withdrawal ^[10][11]. Lawful compounded access generally requires a licensed-prescriber evaluation (telehealth can be the front-end channel), a patient-specific prescription, and an ingredient eligible under the 503A/503B rules — and that ingredient test is the step a withdrawn listing leaves unresolved ^[13].

What is the FDA 503A status of Wolverine (BPC-157 + TB-500)?

FDA placed both constituents in 503A Category 2 in its September 29, 2023 update; the agency's page dated April 22, 2026 shows that their nominators later withdrew the requests ^[11]. Category 2 substances are identified as potentially presenting significant safety risks and are outside FDA's enforcement-discretion policy ^[10]. Both BPC-157 and TB-500 were also up for discussion at the July 23-24, 2026 PCAC meeting as 503A bulks-list candidates — a review, and FDA has published no vote record from it ^[12].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use; both entered 503A Category 2 in 2023, and FDA's current page shows their nominations as withdrawn without spelling out what that means for compounding ^[10][11]. Both are also WADA-prohibited — BPC-157 under the S0 non-approved-substances category and TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories. The blend has no approved therapeutic indication.